logo

Intercept Pharmaceuticals Inc. (ICPT)



Trade ICPT now with
  Date
  Headline
12/13/2019 8:11:53 AM Intercept Submits MAA To EMA For Obeticholic Acid For Fibrosis Due To NASH
12/2/2019 8:19:30 AM Intercept Appoints Jason Campagna Chief Medical Officer
11/25/2019 8:11:27 AM Intercept: FDA Accepts NDA For OCA For Treatment Of Liver Fibrosis Due To NASH And Grants Priority Review
9/9/2019 8:22:32 AM Intercept Appoints Lisa DeFrancesco As VP, Investor Relations
4/4/2019 7:06:23 AM Intercept To Present Results From Phase 3 Trial For Liver Fibrosis Due To NASH At International Liver Congress
2/19/2019 7:14:17 AM Intercept Announces Positive Topline Results From Pivotal Phase 3 REGENERATE Study Of Obeticholic Acid
10/31/2018 7:11:24 AM Intercept Pharma Q3 Net Loss $64.5 Mln, Down From A Net Loss Of $72.6 Mln Last Year
8/6/2018 7:31:38 AM Wedbush Is Raising Intercept Pharmaceuticals Inc. (ICPT) FY18 Rev. Estimate To 178.9 M From 172.6 M
8/6/2018 7:31:13 AM Wedbush Is Cutting Intercept Pharmaceuticals Inc. (ICPT) FY19 Estimate To -9.33 From -9.13
8/6/2018 7:31:00 AM Wedbush Is Cutting Intercept Pharmaceuticals Inc. (ICPT) Q4 19 Estimate To -2.02 From -1.98
8/6/2018 7:30:47 AM Wedbush Is Cutting Intercept Pharmaceuticals Inc. (ICPT) Q3 19 Estimate To -2.23 From -2.18
8/6/2018 7:30:34 AM Wedbush Is Lowering Intercept Pharmaceuticals Inc. (ICPT) Q2 19 Estimate To -2.46 From -2.40
8/6/2018 7:30:22 AM Wedbush Is Lowering Intercept Pharmaceuticals Inc. (ICPT) Q1 19 Estimate To -2.63 From -2.57
  
 
>